Autolus Therapeutics (NASDAQ:AUTL) Sets New 1-Year Low - Here's Why

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) shares reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $2.60 and last traded at $2.65, with a volume of 549381 shares trading hands. The stock had previously closed at $2.69.

Wall Street Analyst Weigh In

A number of brokerages have commented on AUTL. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Needham & Company LLC reiterated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, December 5th. Finally, Redburn Atlantic upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price for the company in a research note on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $10.40.

Autolus Therapeutics Price Performance

The firm has a market cap of $662.56 million, a price-to-earnings ratio of -2.06 and a beta of 1.98. The firm has a fifty day simple moving average of $3.57 and a two-hundred day simple moving average of $3.84.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the prior year, the firm earned ($0.26) EPS. Equities analysts anticipate that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Several large investors have recently added to or reduced their stakes in AUTL. Wellington Management Group LLP increased its stake in shares of Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company's stock worth $87,919,000 after acquiring an additional 6,330,392 shares during the period. Renaissance Technologies LLC grew its position in Autolus Therapeutics by 253.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company's stock worth $3,985,000 after purchasing an additional 821,156 shares during the period. Erste Asset Management GmbH purchased a new position in shares of Autolus Therapeutics during the 3rd quarter valued at about $708,000. FMR LLC lifted its holdings in shares of Autolus Therapeutics by 44.6% in the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company's stock valued at $64,519,000 after buying an additional 5,478,706 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in shares of Autolus Therapeutics in the third quarter worth about $1,082,000. Hedge funds and other institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.